The Same Dose of Anthracycline Is Not Safe for Everyone Not all patients can tolerate the currently recommended cumulative dose of epirubicin. New models can help physicians calculate the epirubicin dose associated with a 5 percent risk of cardiotoxicity for individual patients. Oncologists frequently use anthracyclines, including epirubicin and […]

Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain. The small molecule used in the studies was the drug lapatinib (Tykerb®), which disrupts […]

The ability of Electronic Brachytherapy to accurately and consistently deliver localized, non-radioactive radiation treatment directly to cancer sites is the focus of a symposium and multiple research papers accepted for presentation at […]

Up to 69 percent of men who receive hormone deprivation therapy for prostate cancer will experience some degree of cognitive impairment, such as in the ability to concentrate, a review of published data suggests.

Measuring a woman’s bone mineral density can provide additional information that may help more accurately determine a woman’s risk of developing breast cancer. That is the conclusion of a new study published in the September 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

Cephalon Inc. said Thursday night it filed a patent infringement lawsuit earlier this week against Barr Pharmaceuticals Inc.

The fly-fishing and breastcancer-survivor sisterhood of Bella Vista met for a mini reunion last month at Carol McKibben’s home.

British people may not be not getting enough sunlight to generate sufficient levels of vitamin D, as they are worried about the possibility of skin cancer, according to a poll by the National Osteoporosis Society.

Relay for Life aims to raise $160,000 By Cherie Tham For the Marshfield News-Herald W ith 47 teams already and 529 participants, the American Cancer Society Marshfield Area Relay for Life is gearing up.

The New England Journal of Medicine (NEJM) has today published the results of the Sorafenib HCC Assessment Randomized Protocol (SHARP) Phase 3 trial in which Nexavar® (sorafenib) tablets demonstrated that “survival rates at 1 year were 44% in the sorafenib group and 33% in the placebo group.